Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to Be Presented by Precision Therapeutics at WAGO Annual Meeting

Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to Be Presented by Precision Therapeutics at WAGO Annual Meeting

Precision Therapeutics Inc.Pam Ranallo, 412-432-1500 ext. 1502

, a life science company that develops personalized medicine products for individualizing cancer care, today announced that compelling results from a clinical study which demonstrates whether ChemoFx is an independent predictive factor for progression free survival and overall survival in recurrent ovarian cancer will be presented at the . The meeting will be held from June 27-29, 2013 at the W Seattle in Seattle, Washington.

Patients in the study’s treatment group had their cancer cells tested with the ChemoFx chemoresponse assay to assess tumor response among 12 to 15 clinically equivalent chemotherapy options that cancer guidelines recommend for persistent or recurrent ovarian cancer. While topline results were originally presented at a medical symposium and in a poster session held during the Society of Gynecologic Oncology (SGO) Annual Meeting on March 9-12, 2013 in Los Angeles, California, the comprehensive data will be presented and published in conjunction with the WAGO Annual Meeting in June.

“The significance of this study from a clinical standpoint is that this test may have predictive abilities, enabling a physician to choose the most effective pharmaceutical treatment from among the available options for ovarian cancer,” said .

is a nonprofit organization founded in 1972 to provide a forum for education and dissemination of knowledge about gynecologic oncology.

Precision Therapeutics currently receives ChemoFx specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. Over 60,000 patient specimens to date have been tested with ChemoFx.

, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to utilizing precision medicine for personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s leading products for personalized cancer care include ChemoFx, a chemoresponse assay which measures an individual’s tumor response to a range of therapeutic alternatives and BioSpeciFx, a select portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis. For more information, visit .

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.